Fibroblast growth factor 19–fibroblast growth factor receptor 4 complex (FGF19–FGFR4)

The Fibroblast growth factor 19–fibroblast growth factor receptor 4 (FGF19–FGFR4) complex is a critical endocrine signaling unit primarily involved in the regulation of bile acid homeostasis and metabolic functions within the liver [3, 6]. FGF19 is a hormone-like growth factor produced in the ileum that travels to the liver to bind FGFR4 and its essential co-receptor, beta-Klotho (KLB), initiating a signaling cascade that suppresses the rate-limiting enzyme in bile acid synthesis [2, 16]. Beyond its physiological role, the FGF19–FGFR4 axis is a well-recognized oncogenic driver in a subset of hepatocellular carcinomas (HCC), where FGF19 gene amplification or protein overexpression leads to constitutive pathway activation [4, 5]. This activation promotes tumor cell proliferation, survival, and metastasis through downstream pathways such as MAPK and PI3K/Akt [4, 10]. Therapeutic interventions targeting this complex include selective FGFR4 small-molecule inhibitors designed to treat FGF19-driven cancers, as well as FGF19 analogs developed for metabolic and cholestatic diseases [3, 13]. Selective inhibitors like fisogatinib and roblitinib aim to block the kinase activity of FGFR4 to arrest tumor growth [11, 13]. Conversely, FGF19 analogs like aldafermin act as agonists to restore bile acid regulation in conditions like MASH [3]. However, pharmacological modulation of this complex presents significant challenges, most notably the risk of bile acid-mediated diarrhea and potential hepatotoxicity due to the disruption of normal bile acid feedback mechanisms [16]. Monitoring biomarkers such as FGF19 amplification and serum C4 levels is essential for patient selection and safety management [4, 14].

Other names

FGF19-FGFR4 axisFGF19-FGFR4-KLB complexFGF19-FGFR4 signaling pathwayFibroblast growth factor 19-Fibroblast growth factor receptor 4 complex

Drugs targeting this complex primarily function as selective FGFR4 tyrosine kinase inhibitors (antagonists) to block oncogenic signaling in cancer, or as FGF19 analogs (agonists) to regulate bile acid synthesis and metabolic pathways in liver diseases [3, 13]. Selective inhibitors bind to the ATP-binding pocket of FGFR4, often covalently, to prevent autophosphorylation and downstream activation of the MAPK and PI3K/Akt pathways [11, 13]. Agonists mimic the natural feedback loop of FGF19 to suppress CYP7A1 expression, thereby reducing bile acid production [3, 16].